<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ahc" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ahc</book-part-id>
      <title-group>
        <title>X-Linked Adrenal Hypoplasia Congenita</title>
        <alt-title alt-title-type="alt-title">Synonyms: Adrenal Hypoplasia Congenita, Congenital Adrenal Hypoplasia, X-Linked AHC</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Achermann</surname>
            <given-names>John C</given-names>
          </name>
          <degrees>MB, MD, PhD, FRCPCH</degrees>
          <aff>Clinical and Molecular Genetics<break/>Institute of Child Health<break/>University College London<break/>London, United Kingdom</aff>
          <email>j.achermann@ucl.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vilain</surname>
            <given-names>Eric J</given-names>
          </name>
          <degrees>MD, PhD, FACMG</degrees>
          <aff>Departments of Human Genetics, Pediatrics, and Urology <break/>University of California School of Medicine, Los Angeles<break/>Los Angeles, California</aff>
          <email>evilain@ucla.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>20</day>
          <month>11</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>17</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="revised">
          <day>7</day>
          <month>5</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="wss" document-type="chapter">Woodhouse-Sakati Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="x-ald" document-type="chapter">X-Linked Adrenoleukodystrophy</related-object>
      <abstract id="ahc.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>X-linked adrenal hypoplasia congenita (X-linked AHC) is characterized by infantile-onset acute primary adrenal insufficiency at an average age of three weeks in approximately 60% of affected individuals. Onset in approximately 40% is in childhood. A few individuals present in adulthood with delayed-onset adrenal failure or partial hypogonadism due to partial forms of X-linked AHC. Adrenal insufficiency typically presents acutely in male infants with vomiting, feeding difficulty, dehydration, and shock caused by a salt-wasting episode. Hypoglycemia (sometimes presenting with seizures) or isolated salt loss may be the first symptom of X-linked AHC. Cortisol may be low or within the normal range, which is inappropriately low for a sick child. In older children, adrenal failure may be precipitated by intercurrent illness or stress. If untreated, adrenal insufficiency is rapidly lethal as a result of hyperkalemia, acidosis, hypoglycemia, and shock. Affected males typically have delayed puberty (onset age &#x0003e;14 years) or arrested puberty caused by hypogonadotropic hypogonadism (HH). Early pubertal development with pubertal arrest has been reported in some cases. Males with classic X-linked AHC are infertile despite treatment with exogenous gonadotropin therapy or pulsatile gonadotropin-releasing hormone (GnRH), although testicular sperm extraction-intracytoplasmic sperm injection (TESE-ICSI) has been successful in one case. Carrier females may very occasionally have symptoms of adrenal insufficiency or hypogonadotropic hypogonadism as a result of skewed X-chromosome inactivation.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Primary adrenal failure characterized by hyponatremia, hyperkalemia, acidosis, and an elevated serum concentration of ACTH in the presence of normal or low serum concentration of 17-hydroxyprogesterone presenting in a male in the first month or two of life strongly suggests X-linked AHC. Nearly 100% of affected individuals with a positive family history consistent with X-linked inheritance have an identifiable pathogenic variant in <italic toggle="yes">NR0B1</italic> (previously known as <italic toggle="yes">DAX1</italic>), the only gene in which pathogenic variants are known to cause X-linked AHC. Approximately 50% of males with AHC who have no other affected family members have an identifiable pathogenic variant in <italic toggle="yes">NR0B1</italic>. Individuals with an isolated deletion of <italic toggle="yes">NR0B1</italic> or a contiguous gene deletion including the glycerol kinase gene (<italic toggle="yes">GK</italic>) with or without deletion of <italic toggle="yes">DMD</italic> (the gene encoding dystrophin) can be identified by fluorescent in situ hybridization (FISH) using a <italic toggle="yes">NR0B1</italic> cosmid probe or other deletion/duplication testing methods.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Episodes of acute adrenal insufficiency usually require admission to an intensive care unit with close monitoring of blood pressure, hydration, clinical status, and serum concentration of glucose and electrolytes. Treatment includes the IV administration of saline, glucose, and hydrocortisone. Follow-up includes lifelong replacement doses of glucocorticoids and mineralocorticoids and oral supplements of sodium chloride (NaCl) in younger children. Steroid replacement must be increased during periods of illness or stress. Steroid replacement therapy must be monitored by an endocrinologist and appropriate plans for episodes of sickness should be available. Affected individuals with hypogonadotropic hypogonadism are likely to need increasing doses of testosterone to induce puberty. Long-term management of adrenal steroid replacement and testosterone replacement should be undertaken by an experienced endocrinologist.</p>
          <p><italic toggle="yes">Surveillance</italic>: Monitoring of serum concentrations of LH, FSH, testosterone, and inhibin B if puberty has not started by age 14 years; induction of puberty at a similar time course as the peer group is preferable; monitoring of testosterone levels in those who undergo spontaneous puberty to evaluate for pubertal arrest; psychological counseling to discuss issues related to hormone replacement therapy and fertility.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Unnecessary physiologic stress. Surgical procedures should be carefully planned.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>X-linked adrenal hypoplasia is inherited in an X-linked manner. The risk to sibs depends on the mother's carrier status. If the proband's mother is a carrier, male sibs have a 50% chance of having X-linked AHC and female sibs have a 50% chance of being carriers. Most males with AHC are infertile. Germline mosaicism is possible but uncommon. Carrier testing of at-risk female relatives and prenatal testing for pregnancies of women who are carriers are possible if the <italic toggle="yes">NR0B1</italic> pathogenic variant or deletion has been identified in a family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ahc.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="ahc.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ahc.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">X-Linked Adrenal Hypoplasia Congenita: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ahc.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Complex glycerol kinase deficiency</p></list-item><list-item><p>Isolated X-linked adrenal hypoplasia congenita</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="ahc.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="ahc.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ahc.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>X-linked adrenal hypoplasia congenita (X-linked AHC) is suspected in males presenting in the first (or second) month of life with acute adrenal insufficiency, in males with adrenal failure later in childhood, and in rare cases, in males with partial hypogonadism or delayed-onset adrenal insufficiency presenting in young adulthood.</p>
        </sec>
        <sec id="ahc.Testing">
          <title>Testing</title>
          <p>
            <bold>Adrenal insufficiency</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A high serum ACTH concentration in the presence of a low or normal serum concentration of cortisol is diagnostic of primary adrenal failure. An impaired cortisol response is usually seen after cosyntropin stimulation.</p>
              <p>Note: Measurement of the basal plasma concentration of cortisol is not reliable by itself in the evaluation of an individual with suspected adrenal insufficiency, as the level may be within normal limits. A normal-range cortisol in a clinically sick child is inappropriately low. In some other individuals salt loss may be the presenting feature and cortisol insufficiency may develop with time.</p>
            </list-item>
            <list-item>
              <p>Once primary adrenal insufficiency is diagnosed, further testing is appropriate to distinguish X-linked AHC from the salt-losing form of congenital adrenal hyperplasia (CAH) caused by <related-object link-type="booklink" source-id="gene" document-id="cah" document-type="chapter">21-hydroxylase deficiency</related-object>. The serum concentration of adrenal androgens and the cortisol precursor 17-hydroxyprogesterone are normal or low in X-linked AHC, whereas they are characteristically elevated in 21-hydroxylase deficiency.</p>
            </list-item>
            <list-item>
              <p>Boys presenting with primary adrenal failure in childhood may need to have other causes excluded (see <xref ref-type="sec" rid="ahc.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
            </list-item>
          </list>
          <p><bold>Imaging studies.</bold> Abdominal CT scan or MRI may reveal small adrenal glands. Ultrasound imaging is less specific but avoids radiation exposure inherent in CT imaging and the need for sedation required for MRI imaging in a potentially sick child.</p>
          <p>The apparent absence of the adrenal glands on imaging studies is difficult to interpret, as it may be caused by extreme hypoplasia or aplasia of the adrenal glands, as well as by ectopia of normal-sized adrenal glands.</p>
          <sec id="ahc.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">NR0B1</italic> (historically known as <italic toggle="yes">DAX1</italic>) is the only gene in which pathogenic variants are known to cause isolated X-linked adrenal hypoplasia congenita.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="ahc.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Isolated X-Linked Adrenal Hypoplasia Congenita</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_2">Test Method</th>
                    <th id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_3">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4" id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                    <th headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4" id="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Females</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">NR0B1</italic>
                    </td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Nearly 50%&#x000a0;<sup>5,&#x000a0;6</sup></td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Duplication/deletion analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or whole-gene deletion</td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_1_4 hd_h_ahc.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~10%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ahc.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ahc" object-id="ahc.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ahc.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ahc.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ahc.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="ahc.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="ahc.TF.1.5">
                  <label>5. </label>
                  <p>Lack of amplification by PCRs prior to sequence analysis can suggest a putative deletion of one or more exons or the entire X-linked gene in a male; confirmation may require additional testing by deletion/duplication analysis.</p>
                </fn>
                <fn id="ahc.TF.1.6">
                  <label>6. </label>
                  <p>Negative family history</p>
                </fn>
                <fn id="ahc.TF.1.7">
                  <label>7. </label>
                  <p>Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</p>
                </fn>
                <fn id="ahc.TF.1.8">
                  <label>8. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ahc.TF.1.9">
                  <label>9. </label>
                  <p>Partial, whole-gene, and contiguous gene deletions have been reported. See <related-object source-id="gene" document-id="ahc" object-id="ahc.molgen.TA">HGMD, Table A</related-object>, and <xref ref-type="table" rid="ahc.T.testing_used_in_complex_glycerol_k">Table 2</xref>.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Evaluation for the contiguous gene deletion syndrome, AHC as a part of complex glycerol kinase deficiency.</bold> X-linked AHC may be part of a contiguous gene deletion syndrome (referred to as complex glycerol kinase deficiency) that includes glycerol kinase deficiency (GKD) and, in some individuals, <related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter">Duchenne muscular dystrophy</related-object> (DMD).</p>
            <list list-type="bullet">
              <list-item>
                <p>GKD is diagnosed by measurement of serum concentration of triglycerides and urine glycerol (measured in a urinary organic acids test prepared by solvent extraction method).</p>
              </list-item>
              <list-item>
                <p>DMD is suspected if the serum concentration of creatine kinase (CK) is elevated; the diagnosis is confirmed by molecular genetic testing of <italic toggle="yes">DMD</italic> or, if a pathogenic variant is not identified, immunohistochemical staining of dystrophin on muscle biopsy.</p>
              </list-item>
              <list-item>
                <p><bold>Chromosome analysis.</bold> Routine cytogenetic testing is typically normal in individuals with complex glycerol kinase deficiency, except in rare cases of very large deletions of the short arm of chromosome X involving band Xp21.</p>
              </list-item>
            </list>
            <p><xref ref-type="table" rid="ahc.T.testing_used_in_complex_glycerol_k">Table 2</xref> summarizes FISH testing for this disorder (see also <xref ref-type="table" rid="ahc.T.testing_used_in_complex_glycerol_k"><underline>Table 1</underline></xref>).</p>
            <table-wrap id="ahc.T.testing_used_in_complex_glycerol_k" orientation="portrait" position="anchor">
              <label>Table 2. </label>
              <caption>
                <p>Testing Used in Complex Glycerol Kinase Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Detection Rate in Persons with AHC with Complex GKD</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">NR0B1</italic>
                    </td>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">FISH</td>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Deletion</td>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Whole-gene deletions as a part of a contiguous gene deletion&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_ahc.T.testing_used_in_complex_glycerol_k_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="ahc.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="ahc" object-id="ahc.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="ahc.TF.2.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="ahc.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="ahc.TF.2.3">
                  <label>3. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="ahc.TF.2.4">
                  <label>4. </label>
                  <p>Deletion/duplication analysis and CMA are likely to be more precise in identifying the length of the deleted region and the genes involved.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="ahc.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis of isolated AHC in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Sequencing of <italic toggle="yes">NR0B1</italic> is recommended first.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variant is identified in <italic toggle="yes">NR0B1</italic>, deletion/duplication analysis should be pursued.</p>
            </list-item>
          </list>
          <p><bold>To confirm/establish the diagnosis of complex glycerol kinase deficiency in a proband.</bold> If complex glycerol kinase deficiency is suspected based on clinical symptoms and/or levels of plasma creatine kinase and urine glycerol:</p>
          <list list-type="bullet">
            <list-item>
              <p>FISH for <italic toggle="yes">NR0B1</italic> or a microarray of suitable coverage and resolution is performed first</p>
            </list-item>
            <list-item>
              <p>If no deletion of <italic toggle="yes">NR0B1</italic> is detected by FISH or microarray analysis, deletion/duplication analysis may be pursued next.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variant in the family.</p>
          <p>Note: (1) Carriers are heterozygotes for this X-linked disorder and only in rare cases develop clinical findings related to the disorder as a result of skewed X-inactivation [<xref ref-type="bibr" rid="ahc.REF.shaikh.2008.e1">Shaikh et al 2008</xref>]. (2) Identification of female carriers requires either (a) prior identification of the pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and then, if no pathogenic variant is identified, by methods to detect gross structural abnormalities<italic toggle="yes">.</italic></p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="ahc.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ahc.Clinical_Description">
          <title>Clinical Description</title>
          <p>Most males with X-linked adrenal hypoplasia congenita (AHC) present in shock with acute adrenal insufficiency during the first month or two of life. In one series of 18 affected individuals, the age of onset ranged from one week to three years, with three weeks being the median age of onset [<xref ref-type="bibr" rid="ahc.REF.peter.1998.2666">Peter et al 1998</xref>]. In another series and review of the literature at the time, 48/71 children presented in the first two months of life whereas 23/71presented between age one and nine years [<xref ref-type="bibr" rid="ahc.REF.reutens.1999.504">Reutens et al 1999</xref>]. Intrafamilial variability in age of onset occurs [<xref ref-type="bibr" rid="ahc.REF.wiltshire.2001.1093">Wiltshire et al 2001</xref>], although in families where two brothers are affected the younger one is usually diagnosed earlier as clinical suspicion is greater [<xref ref-type="bibr" rid="ahc.REF.achermann.2001.3171">Achermann et al 2001</xref>]. Exceptional cases present in early adulthood with a primarily reproductive phenotype (i.e., late puberty, infertility) [<xref ref-type="bibr" rid="ahc.REF.tabarin.2000.321">Tabarin et al 2000</xref>] or delayed-onset adrenal failure [<xref ref-type="bibr" rid="ahc.REF.mantovani.2002.44">Mantovani et al 2002</xref>, <xref ref-type="bibr" rid="ahc.REF.ozisik.2003.417">Ozisik et al 2003</xref>, <xref ref-type="bibr" rid="ahc.REF.guclu.2010.1512">Guclu et al 2010</xref>]. In these individuals, residual glucocorticoid and mineralocorticoid activity present in the hypoplastic adrenal cortex may explain the late onset. These individuals may not have overt adrenal dysfunction, but rather only biochemical evidence of compensated adrenal failure (e.g., high serum ACTH concentration) [<xref ref-type="bibr" rid="ahc.REF.mantovani.2002.44">Mantovani et al 2002</xref>]. In some cases, progressive adrenal dysfunction occurs resulting in clinically significant adrenal failure in early adulthood [<xref ref-type="bibr" rid="ahc.REF.guclu.2010.1512">Guclu et al 2010</xref>].</p>
          <p><bold>Adrenal insufficiency.</bold> The initial clinical presentation is typically acute &#x02013; especially in infancy, with vomiting, feeding difficulty, dehydration, and shock caused by a salt-wasting episode. Hypoglycemia, frequently presenting with seizures, may be the first symptom. The initial presentation of adrenal failure is either spontaneous or related to an intercurrent stress (e.g., infection, gastrointestinal disorder, surgery). Mineralocorticoid deficiency may be the presenting feature of X-linked AHC in some cases [<xref ref-type="bibr" rid="ahc.REF.wiltshire.2001.1093">Wiltshire et al 2001</xref>, <xref ref-type="bibr" rid="ahc.REF.verrijn_stuart.2007.755">Verrijn Stuart et al 2007</xref>].</p>
          <p>If untreated with glucocorticoids and mineralocorticoids, adrenal insufficiency is rapidly lethal as a result of hyperkalemia, acidosis, hypoglycemia, and shock. If not recognized and treated, acute adrenal insufficiency and its complications of hypoglycemia and shock may result in neurologic abnormalities and developmental delay. Bilateral infantile striatal necrosis has been reported in rare cases.</p>
          <p>The adrenal insufficiency crisis is usually accompanied by varying degrees of hyperpigmentation caused by increased pituitary production of POMC (proopiomelanocortin). Indeed, the original report of X-linked AHC described an affected newborn with &#x0201c;coal-black hyperpigmentation&#x0201d; of the skin sparing the palms and soles [<xref ref-type="bibr" rid="ahc.REF.sikl.1948.323">Sikl 1948</xref>]. Hyperpigmentation present at the time of diagnosis typically regresses over time with appropriate steroid therapy.</p>
          <p><bold>Hypogonadotropic hypogonadism (HH)</bold> is of mixed hypothalamic and pituitary origin, consistent with the expression of <italic toggle="yes">NR0B1</italic> in the hypothalamus and the pituitary. The "mini puberty" of infancy is normal in affected boys, suggesting that the loss of function of the hypothalamic-pituitary-gonadal axis occurs after early infancy. Cryptorchidism has been reported in several cases but has not emerged as a common feature of X-linked AHC. Indeed, macrophallia (large penis) at birth and some signs of early puberty in childhood have now been reported in a subset of boys with X-linked AHC [<xref ref-type="bibr" rid="ahc.REF.domenice.2001.4068">Domenice et al 2001</xref>, <xref ref-type="bibr" rid="ahc.REF.landau.2010.448">Landau et al 2010</xref>].</p>
          <p>Typically, delayed puberty (onset age &#x0003e;14 years) caused by HH is observed in affected males during adolescence. A proportion of boys may enter puberty and show progression to around Tanner Stage 3 (or 6-8 cc testes) but pubertal arrest at this point is common. Without testosterone treatment, full attainment of secondary sexual characteristics is unlikely to occur and testosterone supplementation is needed to support growth and bone mineralization.</p>
          <p><bold>Fertility</bold> of individuals with AHC has been poorly studied. Azoospermia has been reported in individuals with classic X-linked AHC and severe oligospermia has been found in some individuals with partial forms of this condition [<xref ref-type="bibr" rid="ahc.REF.tabarin.2000.321">Tabarin et al 2000</xref>]. Treatment of HH with exogenous gonadotropin therapy or pulsatile GnRH has not restored normal spermatogenesis [<xref ref-type="bibr" rid="ahc.REF.seminara.1999.4501">Seminara et al 1999</xref>, <xref ref-type="bibr" rid="ahc.REF.mantovani.2006.685">Mantovani et al 2006</xref>].</p>
          <p>Recently, fertility was achieved in a man with classic early-onset X-linked AHC who underwent testicular sperm extraction-intracytoplasmic sperm injection (TESE-ICSI) having had fairly extensive gonadotropin treatment in the past [<xref ref-type="bibr" rid="ahc.REF.frapsauce.2011.724">Frapsauce et al 2011</xref>]. It is not yet known whether this success will be possible in general or whether this represents an isolated case. See <xref ref-type="sec" rid="ahc.Genetic_Counseling">Genetic Counseling</xref> for issues related to recurrence risks for children born to affected men.</p>
          <p><bold>Developmental delay</bold> may be seen in individuals with X-linked AHC. Its occurrence is related to two factors: the initial medical management of adrenal insufficiency and the type of genetic defect. Large deletions of Xp may include, in addition to <italic toggle="yes">NR0B1</italic>, a locus responsible for intellectual disability (e.g. <italic toggle="yes">IL1RAPL1</italic>). Deletion of this latter locus may be responsible for developmental delay in some individuals with X-linked AHC.</p>
          <p><bold>Hearing loss.</bold> Progressive high-frequency sensorineural hearing loss starting at about age 14 years has been described in two individuals whose <italic toggle="yes">NR0B1</italic> status is unknown [<xref ref-type="bibr" rid="ahc.REF.zachmann.1992.167">Zachmann et al 1992</xref>, <xref ref-type="bibr" rid="ahc.REF.liotta.1995.471">Liotta et al 1995</xref>]. To the authors&#x02019; knowledge no further cases of hearing loss associated with classic X-linked AHC have been reported.</p>
          <p><bold>Other.</bold> In one male with a missense pathogenic variant in <italic toggle="yes">NR0B1</italic>, tall stature and renal ectopy were associated with adrenal insufficiency [<xref ref-type="bibr" rid="ahc.REF.franzese.2005.72">Franzese et al 2005</xref>].</p>
          <p><bold>Carrier females</bold> may very occasionally have symptoms of adrenal insufficiency or hypogonadotropic hypogonadism, potentially caused by skewed X-chromosome inactivation. In one instance, a female homozygous for a <italic toggle="yes">NR0B1</italic> pathogenic variant (which may result from gene conversion) had isolated hypogonadotropic hypogonadism [<xref ref-type="bibr" rid="ahc.REF.merke.1999.1248">Merke et al 1999</xref>]. Two nephews with the same pathogenic variant had the complete AHC syndrome. Another carrier female presenting with extreme pubertal delay has been described [<xref ref-type="bibr" rid="ahc.REF.seminara.1999.4501">Seminara et al 1999</xref>].</p>
          <p>A girl with mild adrenal failure and <related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter">Duchenne muscular dystrophy</related-object> has also been reported [<xref ref-type="bibr" rid="ahc.REF.shaikh.2008.e1">Shaikh et al 2008</xref>]. In this case molecular studies were performed to confirm extremely skewed X-chromosome inactivation in the region of Xp21 that resulted in differential expression of the disrupted allele.</p>
          <p><bold>Histopathology.</bold> The adrenal cortex may be structurally disorganized with irregular nodular formations of eosinophilic cells and a nearly absent adult cortex. This is described as the cytomegalic form of AHC, as the remaining cells resemble the large cells typically seen in the fetal adrenal gland [<xref ref-type="bibr" rid="ahc.REF.sikl.1948.323">Sikl 1948</xref>].</p>
        </sec>
        <sec id="ahc.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>In X-linked AHC caused by a single nucleotide variant in <italic toggle="yes">NR0B1</italic> no clear correlation exists between the location or type of variant and the clinical phenotype.</p>
          <list list-type="bullet">
            <list-item>
              <p>Some cases of late-onset X-linked AHC can result from single nucleotide variants in the ligand-like binding region of <italic toggle="yes">NR0B1</italic> around the hydrophobic core (e.g., p.Tyr380Asp, p.Ile439Ser) [<xref ref-type="bibr" rid="ahc.REF.tabarin.2000.321">Tabarin et al 2000</xref>, <xref ref-type="bibr" rid="ahc.REF.achermann.2001.3171">Achermann et al 2001</xref>, <xref ref-type="bibr" rid="ahc.REF.mantovani.2002.44">Mantovani et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Milder forms may also occur as a result of nonsense variants at the amino-terminal region of <italic toggle="yes">NR0B1</italic> (e.g. stop codons at position 37 or 39) [<xref ref-type="bibr" rid="ahc.REF.ozisik.2003.417">Ozisik et al 2003</xref>, <xref ref-type="bibr" rid="ahc.REF.guclu.2010.1512">Guclu et al 2010</xref>]. It has been proposed that translation re-initiation from a methionine at codon 83 produces an amino-terminally truncated protein with partially conserved function [<xref ref-type="bibr" rid="ahc.REF.ozisik.2003.417">Ozisik et al 2003</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ahc.Nomenclature">
          <title>Nomenclature</title>
          <p>The term "congenital adrenal hypoplasia" is used less and less because it is easily confused with the much more common disorder, <related-object link-type="booklink" source-id="gene" document-id="cah" document-type="chapter">congenital adrenal hyperplasia</related-object>. Both terms can be abbreviated as "CAH," further adding to potential confusion. Thus, adrenal hypoplasia congenita (AHC) is the preferred term.</p>
        </sec>
        <sec id="ahc.Prevalence">
          <title>Prevalence</title>
          <p>The incidence of X-linked AHC is unknown. It has been widely estimated at 1:12,500 live births [<xref ref-type="bibr" rid="ahc.REF.mccabe.2001">McCabe 2001</xref>], but such figures were based on limited historic data that included secondary forms of AHC and anencephaly. Other estimates have put the figure at less than 1:70,000 males [<xref ref-type="bibr" rid="ahc.REF.lin.2006.3048">Lin et al 2006</xref>]. No specific populations are known to be at greater or lesser risk for this disorder.</p>
        </sec>
      </sec>
      <sec id="ahc.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be caused by pathogenic variants or deletions in <italic toggle="yes">NR0B1</italic>.</p>
      </sec>
      <sec id="ahc.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis includes congenital adrenal hyperplasia (CAH) caused by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The salt-losing form of <related-object link-type="booklink" source-id="gene" document-id="cah" document-type="chapter">21-hydroxylase deficiency</related-object> (21-OHD), the most common disorder to consider in the differential diagnosis of X-linked AHC. 21-OHD also typically presents with an acute, salt-wasting episode of adrenal insufficiency in the neonatal period. Serum concentration of cortisol precursors (e.g., 17-OH progesterone) are elevated in 21-OHD, but normal or low in X-linked AHC. 21-OHD is inherited in an autosomal recessive manner.</p>
          </list-item>
          <list-item>
            <p>Deficiency in 11-hydroxylase, in which affected individuals may experience a transient salt-losing phase before salt retention occurs</p>
          </list-item>
        </list>
        <p>The following disorders may present with symptoms similar to those seen in X-linked AHC:</p>
        <list list-type="bullet">
          <list-item>
            <p>ACTH deficiency presents with glucocorticoid (but not mineralocorticoid) insufficiency and low or unmeasurable serum concentration of ACTH (with and without corticotropin-releasing hormone stimulation). Isolated ACTH deficiency can result from alterations in <italic toggle="yes">TBX19</italic>, <italic toggle="yes">POMC</italic>, or <italic toggle="yes">PCSK1</italic>. ACTH deficiency can also occur as part of multiple pituitary hormone deficiency.</p>
          </list-item>
          <list-item>
            <p>Congenital adrenal lipoid hyperplasia may present with salt-losing adrenal failure in a manner similar to AHC. Congenital adrenal lipoid hyperplasia is caused either by mutation of the gene encoding steroidogenic acute regulatory protein (StAR) or by CYP11A1 deficiency. Individuals with disruption of StAR or CYP11A1 and a 46,XY karyotype classically have ambiguous genitalia or female external genitalia. Adrenal imaging usually reveals enlarged and fatty adrenal glands. However, milder defects in <italic toggle="yes">STAR</italic> or <italic toggle="yes">CYP11A1</italic> (or in <italic toggle="yes">HSD3B2</italic>) can be found in males with either hypospadias or &#x0201c;normal&#x0201d; male genitalia and delayed-onset adrenal failure in childhood. Usually, the salt-loss is not severe in these cases.</p>
          </list-item>
          <list-item>
            <p>Adrenal hypoplasia congenita, autosomal recessive form is the "miniature adult" type of adrenal hypoplasia; the adrenal cortex is composed of a small amount of permanent adult cortex. The molecular basis of this condition is currently unknown.</p>
          </list-item>
          <list-item>
            <p>Familial glucocorticoid deficiency and ACTH resistance is caused by mutation of <italic toggle="yes">MC2R</italic> encoding the ACTH receptor, disruption of the MC2R accessory protein (MRAP), or disruption of nicotinamide nucleotide transhydrogenase (<italic toggle="yes">NNT</italic>) [<xref ref-type="bibr" rid="ahc.REF.meimaridou.2012.740">Meimaridou et al 2012</xref>]. This form of adrenal hypoplasia usually has normal mineralocorticoid secretion, although transient hyponatremia can be seen in severe cases.</p>
          </list-item>
        </list>
        <p>Several syndromes and chromosomal abnormalities have AHC or AHC-like symptoms as one feature:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pena-Shokeir syndrome, type 1 (fetal akinesia deformation sequence) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/208150">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hpe-overview" document-type="chapter">Holoprosencephaly</related-object>, alobar type</p>
          </list-item>
          <list-item>
            <p>Meckel syndrome (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/249000">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>SerKAL (46,XX <italic toggle="yes">se</italic>x-<italic toggle="yes">r</italic>eversal.with dysgenesis of <italic toggle="yes">k</italic>idneys, <italic toggle="yes">a</italic>drenals, and <italic toggle="yes">l</italic>ungs) caused by mutation of <italic toggle="yes">WNT4</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/611812">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="image" document-type="chapter">IMAGe syndrome</related-object> (<italic toggle="yes">i</italic>ntrauterine growth retardation, <italic toggle="yes">m</italic>etaphyseal dysplasia, <italic toggle="yes">A</italic>HC, <italic toggle="yes">ge</italic>nital abnormalities) caused by mutation of <italic toggle="yes">CDKN1C</italic> [<xref ref-type="bibr" rid="ahc.REF.arboleda.2012.788">Arboleda et al 2012</xref>]. Growth restriction is a key component of this condition.</p>
          </list-item>
          <list-item>
            <p>Triple A (<italic toggle="yes">a</italic>chalasia, <italic toggle="yes">a</italic>ddisonianism, <italic toggle="yes">a</italic>lachrima) or Allgrove syndrome caused by mutation of <italic toggle="yes">AAAS</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231550">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Natural killer cell and glucocorticoid deficiency with DNA repair defect (NKGCD) caused by disruption of minichromosome maintainance-4 (<italic toggle="yes">MCM4</italic>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/609981">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Chromosomal abnormalities, including tetraploidy, triploidy, trisomy 19, trisomy 21, 5p duplication, monosomy 7, and 11q- syndrome</p>
          </list-item>
        </list>
        <p>Other forms of primary adrenal failure may need to be considered in boys presenting with primary adrenal failure:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD) affects the nervous system white matter and the adrenal cortex. Three main phenotypes are seen in affected males. The childhood cerebral form manifests most commonly between ages four and eight years. It initially resembles attention deficit disorder or hyperactivity; progressive impairment of cognition, behavior, vision, hearing, and motor function follow the initial symptoms and often lead to total disability within two years. Adrenomyeloneuropathy (AMN) manifests most commonly in the late twenties as progressive paraparesis, sphincter disturbances, sexual dysfunction, and often, impaired adrenocortical function; all symptoms are progressive over decades. "Addison disease only" presents with primary adrenocortical insufficiency between age two years and adulthood and most commonly by age 7.5 years, without evidence of neurologic abnormality; however, some degree of neurologic disability (most commonly AMN) usually develops later. Approximately 20% of females who are carriers develop neurologic manifestations that resemble AMN but have later onset (age &#x02265;35 years) and milder disease than do affected males.</p>
          </list-item>
          <list-item>
            <p>Other metabolic causes (e.g. <related-object link-type="booklink" source-id="gene" document-id="lal-def" document-type="chapter">Wolman disease</related-object>, mitochondrial disease, <related-object link-type="booklink" source-id="gene" document-id="slo" document-type="chapter">Smith-Lemli-Opitz syndrome</related-object>)</p>
          </list-item>
          <list-item>
            <p>Autoimmune syndromes (e.g., polyglandular endocrine disease caused by mutation of <italic toggle="yes">AIRE</italic>)</p>
          </list-item>
          <list-item>
            <p>Extrinsic (e.g., mechanical, infective, or drug-related) causes</p>
          </list-item>
        </list>
      </sec>
      <sec id="ahc.Management">
        <title>Management</title>
        <sec id="ahc.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To assess the extent of disease and needs in an individual diagnosed with X-linked adrenal hypoplasia congenita (AHC), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Serum and urine concentrations of electrolytes</p>
            </list-item>
            <list-item>
              <p>Assessment of renal function, including measurement of serum BUN and creatinine</p>
            </list-item>
            <list-item>
              <p>Serum concentration of glucose, cortisol and ACTH</p>
            </list-item>
            <list-item>
              <p>Assessment of arterial blood gases in those who are unwell</p>
            </list-item>
            <list-item>
              <p>Measurement of aldosterone and plasma renin activity</p>
            </list-item>
          </list>
          <p>Note: Typically, affected individuals who are in shock have hyponatremia, hyperkalemia, hypoglycemia, acidosis, very elevated serum concentration of ACTH, and increased urinary excretion of sodium. Some samples may need careful handling (e.g., ACTH) and results may only be available some days later. Therefore, it is important to document the child&#x02019;s clinical condition at the time of sample collection, the source of the sample (e.g., venous, arterial), and the quality of the sample (e.g., hemolyzed) to help with future interpretation of the results.</p>
        </sec>
        <sec id="ahc.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="ahc.Adrenal_Insufficiency">
            <title>Adrenal Insufficiency</title>
            <p><bold>Acute episodes.</bold> Episodes of acute adrenal insufficiency are usually treated in an intensive care unit with close monitoring of blood pressure, hydration, clinical status, and serum concentration of glucose and electrolytes. Correction of hyperkalemia may be needed. Individuals are treated by the IV administration of saline, glucose, and hydrocortisone (e.g., Solu-Cortef<sup>&#x000ae;</sup>). If the serum concentration of electrolytes does not improve, a mineralocorticoid (fludrocortisone) is added or the dose of Solu-Cortef<sup>&#x000ae;</sup> is increased. Adequate sodium must be provided.</p>
            <p><bold>Chronic treatment</bold>. Once the initial acute episode has been treated, affected individuals are started on replacement doses of glucocorticoids and mineralocorticoids, and oral supplements of sodium chloride (NaCl) in younger children.</p>
            <list list-type="bullet">
              <list-item>
                <p>Steroid doses need to be adjusted to allow normal linear growth without risking an adrenal crisis.</p>
              </list-item>
              <list-item>
                <p>Maintenance hormone treatment is best managed in growing children by a pediatric endocrinologist.</p>
              </list-item>
            </list>
            <p><bold>Treatment during stress.</bold> Steroid dosage must be increased during periods of stress (e.g., intercurrent illness, surgery, trauma); glucose and sodium may be needed.</p>
            <list list-type="bullet">
              <list-item>
                <p>Local hospitals should provide parents with a plan for emergency treatment and instruction regarding when extra oral or injected hydrocortisone is needed. Parents should have access to rapid medical advice; guidelines for hospital admission should be clear.</p>
              </list-item>
              <list-item>
                <p>Children should carry appropriate documentation indicating that they are steroid deficient. Death from acute adrenal insufficiency in individuals known to have X-linked adrenal hypoplasia congenita may still occur if steroid replacement therapy is not adequate, particularly during times of stress.</p>
              </list-item>
            </list>
            <p>Steroid replacement therapy is monitored clinically and hormonally by an endocrinologist. ACTH levels should normalize when replacement therapy is adequate. A sudden rise in ACTH despite steroid treatment has revealed the presence of a pituitary adenoma in one case [<xref ref-type="bibr" rid="ahc.REF.de_menis.2005.211">De Menis et al 2005</xref>].</p>
            <p>The wearing of a Medic Alert<sup>&#x000ae;</sup> bracelet is strongly recommended.</p>
          </sec>
          <sec id="ahc.Hypogonadotropic_Hypogonadism">
            <title>Hypogonadotropic Hypogonadism</title>
            <p>If there is evidence of HH, treatment with increasing doses of testosterone to induce puberty may be necessary and should be monitored by a pediatric endocrinologist.</p>
          </sec>
        </sec>
        <sec id="ahc.Surveillance">
          <title>Surveillance</title>
          <p>If puberty has not started by age 14 years, serum concentrations of LH and FSH (basal concentration and GnRH-stimulated concentration), testosterone, and inhibin B are monitored to evaluate for the possibility of HH.</p>
          <list list-type="bullet">
            <list-item>
              <p>Some children and parents prefer the induction of puberty at the same time as the affected boy&#x02019;s peer-group; this should not be delayed unnecessarily.</p>
            </list-item>
            <list-item>
              <p>If puberty does start spontaneously it is likely to arrest; thus, careful monitoring of testosterone levels is needed.</p>
            </list-item>
            <list-item>
              <p>Psychological counseling should be available for families and young people if needed to discuss the issues related to hormone replacement therapy and future fertility.</p>
            </list-item>
          </list>
        </sec>
        <sec id="ahc.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Unnecessary physiologic stress is to be avoided, if possible, and any surgical procedures should be carefully planned. If physiologic stress is unavoidable (e.g., surgery, febrile illness, trauma), the dosage of steroids should be increased two- to threefold following local guidance for sickness/emergencies.</p>
        </sec>
        <sec id="ahc.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the genetic status of an at-risk male relative has not been established during pregnancy, genetic testing should be performed as soon as possible after birth to clarify genetic status so that glucocorticoid and mineralocorticoid hormone replacement therapy can be initiated without delay and adrenal crises can be avoided. Biochemical testing after birth should be undertaken if the genetic status of an at-risk male is unknown and the child should be closely monitored in the first few days of life. A salt-losing crisis usually takes at least seven days to manifest, during which the child is continuing to lose sodium. Initial biochemical tests of electrolytes and basal cortisol may be within normal ranges but may gradually change. The aim is to avoid a clinical salt-losing crisis.</p>
          <p>See <xref ref-type="sec" rid="ahc.Related_Genetic_Counseling_Issues"><underline>Genetic Counseling</underline></xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ahc.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/"><underline>ClinicalTrials.gov</underline></ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="ahc.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ahc.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>X-linked adrenal hypoplasia is inherited in an X-linked manner.</p>
        </sec>
        <sec id="ahc.Risk_to_Family_Members__Isolated_XLi">
          <title>Risk to Family Members &#x02014; Isolated X-Linked AHC</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have X-linked adrenal hypoplasia nor will he be a carrier of the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected individual is an obligate carrier.</p>
            </list-item>
            <list-item>
              <p>If there is only one affected individual in the family, the mother may be a carrier or the affected individual may have a <italic toggle="yes">de novo</italic> pathogenic variant, in which case the mother is not a carrier.</p>
            </list-item>
            <list-item>
              <p>The percent of male probands with a negative family history in whom mutation occurred <italic toggle="yes">de novo</italic> is unknown but probably low.</p>
            </list-item>
            <list-item>
              <p>Carrier females may occasionally have symptoms of adrenal insufficiency or hypogonadotropic hypogonadism, possibly caused by skewed X-chromosome inactivation or gene conversion.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to sibs depends on the mother's carrier status.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the proband's mother is a carrier, each male sib has a 50% chance of having X-linked AHC and each female sib has a 50% chance of being a carrier.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism is possible but uncommon. If the pathogenic variant found in the proband cannot be detected in the DNA of the mother of the only affected male in the family, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Most males with AHC are infertile secondary to HH and a primary seminiferous tubule defect; however, should a male conceive through assisted reproductive technologies, all daughters will be carriers of the <italic toggle="yes">NR0B1</italic> pathogenic variant. No son will inherit the pathogenic variant in <italic toggle="yes">NR0B1</italic>.</p>
          <p><bold>Other family members of a proband.</bold> The proband's maternal aunts and their offspring may be at risk of being carriers or of being affected (depending on their gender and family relationship and the carrier status of the proband's mother).</p>
        </sec>
        <sec id="ahc.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible for at-risk women in families in whom the affected family member has a single nucleotide variant in <italic toggle="yes">NR0B1</italic>.</p>
          <p>Carrier testing is possible for at-risk women in families in whom the affected family member has a deletion detectable either by FISH studies using a <italic toggle="yes">NR0B1</italic> cosmid probe or by other deletion/duplication analysis methods.</p>
        </sec>
        <sec id="ahc.Risk_to_Family_Members__Complex_Glyc">
          <title>Risk to Family Members &#x02014; Complex Glycerol Kinase Deficiency</title>
          <p>The specific deletion in a family runs true in the family. Some families have deletions involving <italic toggle="yes">NR0B1</italic>, <italic toggle="yes">GK</italic>, and <italic toggle="yes">DMD</italic> (mutation of which results in AHC, GKD, and DMD respectively) while other families may have deletions that include <italic toggle="yes">NR0B1</italic> and <italic toggle="yes">GK</italic> only<italic toggle="yes">.</italic></p>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most mothers of individuals diagnosed with complex glycerol kinase deficiency are carriers; however, a proband may have the disorder as the result of a <italic toggle="yes">de novo</italic> deletion.</p>
            </list-item>
            <list-item>
              <p>The proportion of cases caused by <italic toggle="yes">de novo</italic> deletions is unknown.</p>
            </list-item>
            <list-item>
              <p>Evaluation of the mother of a child with complex glycerol kinase deficiency and no known family history of complex glycerol kinase deficiency should include FISH studies using a <italic toggle="yes">NR0B1</italic> cosmid probe.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the carrier status of the mother:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother is a carrier of the deletion, each male sib is at a 50% risk of being affected and each female sib is at a 50% risk of being a carrier.</p>
            </list-item>
            <list-item>
              <p>If the mother does not have the deletion, the risk to the sibs is essentially zero.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Males with complex GKD do not reproduce as they typically die in adolescence or young adulthood of complications from DMD, or are severely ill.</p>
          <p><bold>Other family members of a proband.</bold> The proband's maternal aunts and their offspring may be at risk of being carriers or of being affected (depending on their gender, family relationship, and the carrier status of the proband's mother).</p>
        </sec>
        <sec id="ahc.Carrier_Detection_1">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible for at-risk women in families in whom the affected family member has a contiguous gene deletion syndrome detectable by FISH studies or by other deletion/duplication analysis methods.</p>
        </sec>
        <sec id="ahc.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See <xref ref-type="sec" rid="ahc.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Pedigree analysis.</bold> An in-depth family history may identify as-yet-untested male relatives possibly at risk of developing adrenal insufficiency.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ahc.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Isolated X-linked AHC.</bold> Once the <italic toggle="yes">NROB1</italic> pathogenic variant has been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for X-linked AHC are possible.</p>
          <p><bold>Complex glycerol kinase deficiency.</bold> Once the <italic toggle="yes">NROB1</italic> pathogenic deletion has been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
        </sec>
      </sec>
      <sec id="ahc.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ahc.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The <italic toggle="yes">NR0B1</italic> reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000475.4">NM_000475.4</ext-link> has two exons and contains one open reading frame that starts at the ATG codon (nucleotide 1) and ends at the TAA stop codon (nucleotide 1410). A single intron of 3 kb is inserted between nucleotides 1167 and 1168. A novel isoform of <italic toggle="yes">NR0B1</italic> has been described. It is encoded by the known exon 1 of <italic toggle="yes">NR0B1</italic> and a previously unrecognized exon 2a present within intron 1. This novel transcript encodes the first 389 amino acids by exon 1 and the last 12 by exon 2a, and is expressed in the adrenal gland, brain, kidney, ovary, and testis [<xref ref-type="bibr" rid="ahc.REF.ho.2004.330">Ho et al 2004</xref>, <xref ref-type="bibr" rid="ahc.REF.hossain.2004.1428">Hossain et al 2004</xref>]. The biologic significance of this transcript is unclear.</p>
        <p><italic toggle="yes">NR0B1</italic> is the standard name for the gene but it has historically been known as <italic toggle="yes">DAX1</italic> (and sometimes <italic toggle="yes">Ahch</italic>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ahc" object-id="ahc.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> In a series of 18 affected individuals from 16 families with X-linked adrenal hypoplasia congenita (AHC), seven families had deletions of <italic toggle="yes">NR0B1</italic> (2 limited to <italic toggle="yes">NR0B1</italic>, 1 extending to <italic toggle="yes">GK</italic>, and 4 including <italic toggle="yes">NR0B1</italic>, <italic toggle="yes">GK</italic>, and <italic toggle="yes">DMD</italic>) and seven families had an intragenic pathogenic variant. In one family, no <italic toggle="yes">NR0B1</italic> pathogenic variant was found; in one family, no analysis for pathogenic variants was performed.</p>
        <p>In a review of 42 intragenic pathogenic variants in <italic toggle="yes">NR0B1</italic> found in 48 families, 23 were frameshift variants and 12 were nonsense variants, all distributed throughout <italic toggle="yes">NR0B1</italic> [<xref ref-type="bibr" rid="ahc.REF.zhang.1998.855">Zhang et al 1998</xref>]. The six missense variants and one single-codon in-frame deletion all mapped to the C-terminal part of <italic toggle="yes">NR0B1</italic>, in the hydrophobic core of the putative ligand-binding domain. Three additional variants that cluster to the C-terminal region of <italic toggle="yes">NR0B1</italic> have been described [<xref ref-type="bibr" rid="ahc.REF.achermann.2001.3171">Achermann et al 2001</xref>]. Many novel pathogenic variants have recently been described [<xref ref-type="bibr" rid="ahc.REF.balsamo.2005.292">Balsamo et al 2005</xref>, <xref ref-type="bibr" rid="ahc.REF.choi.2005.200">Choi et al 2005</xref>, <xref ref-type="bibr" rid="ahc.REF.tsai.2005.991">Tsai &#x00026; Tung 2005</xref>, <xref ref-type="bibr" rid="ahc.REF.calvari.2006.41">Calvari et al 2006</xref>, <xref ref-type="bibr" rid="ahc.REF.mantovani.2006.685">Mantovani et al 2006</xref>]. Interestingly, only one missense variant (C200W) outside the ligand binding was described, in a female age eight years with late-onset AHC. Her father, hemizygous for the variant, had no overt adrenal phenotype, yet the p.Cys200Trp variant impaired subcellular localization of <italic toggle="yes">NR0B1</italic>, shifting it towards the cytoplasm [<xref ref-type="bibr" rid="ahc.REF.bernard.2006.272">Bernard et al 2006</xref>].</p>
        <p>In a review of ten years&#x02019; experience of the analysis of <italic toggle="yes">NR0B1</italic> in adrenal failure, <xref ref-type="bibr" rid="ahc.REF.lin.2006.3048">Lin et al [2006]</xref> described 37 new cases of X-linked AHC and reviewed the published literature. They reported that <italic toggle="yes">NR0B1</italic> pathogenic variants or deletions were found in 58% of boys who had a diagnosis of AHC. All eight cases where there was a family history of X-linked adrenal failure and HH had <italic toggle="yes">NR0B1</italic> pathogenic variants, but <italic toggle="yes">NR0B1</italic> pathogenic variants were also found in around 40% of boys who had yet to reach adolescence and where there was no family history reported. A review of 190 published cases showed that the proportion of contiguous gene deletion cases was high (38%) and that of isolated
<italic toggle="yes">NR0B1</italic> deletions was low (5%), which probably reflects diagnosis and publication bias for complex glycerol kinase deficiency in the past. In the series of 37 new cases described, only two (5%) had contiguous deletions whereas eight (22%) had isolated deletions of <italic toggle="yes">NR0B1</italic>. Overall, in both series, frameshift variants were slightly more prevalent than nonsense or missense variants. No pathogenic variants in <italic toggle="yes">NR0B1</italic> were found in a cohort of adult patients with isolated primary adrenal insufficiency of unknown etiology.</p>
        <p>Pathogenic variants described in this section include (but are not limited to) the variants in the OMIM entry <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/300473">300473</ext-link>.</p>
        <p><bold>Normal gene product.</bold> The predicted size of the protein product <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000466.2">NP_000466.2</ext-link> is 470 amino acids. The protein encoded by <italic toggle="yes">NR0B1</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000475.4">NM_000475.4</ext-link>) has the structure of a transcription factor and is classified as an orphan nuclear receptor.</p>
        <p>The carboxyl-terminal region of NR0B1 has a structure similar to the ligand-binding domains of nuclear receptors. The amino-terminal region of NR0B1 contains repeat motifs and lacks a typical DNA-binding domain found in other nuclear receptors. Although some studies have shown that NR0B1 can bind to DNA through hairpin loops, others have shown that NR0B1 can interact directly with other factors and co-factors (e.g., NR5A1/steroidogenic factor-1) or other cellular components (e.g., polyribosomes in complexes with polyadenylated RNA). Recently, crystal studies have shown that NR0B1 can bind to NR5A2 directly as part of a complex involving two NR0B1 transcripts [<xref ref-type="bibr" rid="ahc.REF.sablin.2008.18390">Sablin et al 2008</xref>].</p>
        <p>Nuclear receptor 0B1 plays an important role in the normal development of the adrenal glands, the hypothalamus, the pituitary, and the ovary and testis and is expressed in these tissues during development and into post-natal life. The exact biologic role of NR0B1 is unknown. Initial studies have shown that NR0B1 can act as a negative regulator of other nuclear receptor signaling pathways. For instance, nuclear receptor 0B1 inhibits transactivation mediated by steroidogenic factor 1 (SF1), and may act as a negative co-regulator of estrogen receptor (ER, NR3A1-2), liver receptor homologue-1 (LRH-1, NR5A2), androgen receptor (AR, NR3C4), and progesterone receptor (PR, NR3C3), each by distinct repression mechanisms [<xref ref-type="bibr" rid="ahc.REF.iyer.2004.60">Iyer &#x00026; McCabe 2004</xref>]. Nuclear receptor 0B1 may also act as a transcriptional repressor of other important target genes such as steroidogenic acute regulatory protein (STAR), aromatase, and LH beta [<xref ref-type="bibr" rid="ahc.REF.wang.2001.7988">Wang et al 2001</xref>].</p>
        <p>These repressor effects are paradoxic, as loss of NR0B1 function causes adrenal underdevelopment and endocrine dysfunction. Several more recent studies have shown that NR0B1 can activate gene transcription in certain in vitro biologic assay systems or on specific promoters [<xref ref-type="bibr" rid="ahc.REF.verrijn_stuart.2007.755">Verrijn Stuart et al 2007</xref>, Ferraz de Souza et al 2009, <xref ref-type="bibr" rid="ahc.REF.xu.2009.1719">Xu et al 2009</xref>].</p>
        <p>An alternative hypothesis is that NR0B1 acts as a repressor of cell cycle progression and in the differentiation of pluripotent stem cells in the developing tissues [<xref ref-type="bibr" rid="ahc.REF.lalli.2003.1445">Lalli &#x00026; Sassone-Corsi 2003</xref>]. Early differentiation of these cells into mature cells without prior expansion of cell numbers could lead to early overactivity and then to subsequent hypoplasia of the organ and depletion of the pluripotent cell pool. Some evidence for this hypothesis comes from a mouse model of <italic toggle="yes">Nr0b1</italic> (exon 2) deletion [<xref ref-type="bibr" rid="ahc.REF.scheys.2011.3430">Scheys et al 2011</xref>].</p>
        <p>In addition to its role in the pathogenesis of X-linked AHC, <italic toggle="yes">NR0B1</italic> plays a major role in sex determination. <italic toggle="yes">NR0B1</italic> is located in the DSS locus, a 160-kb region in Xp21 responsible, when duplicated, for dosage-sensitive sex reversal. NR0B1 has been hypothesized to act as an antagonist of SRY, the main male sex-determining gene.</p>
        <p><bold>Abnormal gene product.</bold> When <italic toggle="yes">NR0B1</italic> has an inactivating pathogenic variant (deletion, nonsense, frameshift), no nuclear receptor 0B1 or truncated nuclear receptor 0B1 is made. When a missense variant is present in <italic toggle="yes">NR0B1</italic>, it is predicted to have a deleterious effect on the normal conformation and function of nuclear receptor 0B1, or to affect nuclear localization of the protein.</p>
      </sec>
      <sec id="ahc.References">
        <title>References</title>
        <sec id="ahc.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ahc.Literature_Cited.reflist0">
            <ref id="ahc.REF.achermann.2001.3171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silverman</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habiby</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosler</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Missense mutations cluster within the carboxyl-terminal region of DAX-1 and impair transcriptional repression.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>86</volume>
                <fpage>3171</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11443184</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.arboleda.2012.788">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arboleda</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parnaik</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banerjee</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferraz-de-Souza</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000e9;lot</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez-Fernandez</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braslavsky</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergad&#x000e1;</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell'Angelica</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Agosto</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilain</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>44</volume>
                <fpage>788</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">22634751</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.balsamo.2005.292">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Balsamo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antelli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldazzi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baronio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazareva</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cicognani</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A new DAX1 gene mutation associated with congenital adrenal hypoplasia and hypogonadotropic hypogonadism.</article-title>
                <source>Am J Med Genet A</source>
                <volume>135</volume>
                <fpage>292</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15884018</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.bernard.2006.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bernard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludbrook</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Queipo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dinulos</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kletter</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phelan</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harley</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilain</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A familial missense mutation in the hinge region of DAX1 associated with late-onset AHC in a prepubertal female.</article-title>
                <source>Mol Genet Metab</source>
                <volume>88</volume>
                <fpage>272</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16459121</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.calvari.2006.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calvari</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alpigiani</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poggi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Podesta</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camerino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorini</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism: report on new mutation of the DAX-1 gene in two siblings.</article-title>
                <source>J Endocrinol Invest</source>
                <volume>29</volume>
                <fpage>41</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16553032</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.choi.2005.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oh</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoo</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Identification of novel mutations of the DAX-1 gene in patients with X-linked adrenal hypoplasia congenita.</article-title>
                <source>Horm Res</source>
                <volume>63</volume>
                <fpage>200</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15860922</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.de_menis.2005.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncaroli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvari</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiarini</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauletto</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camerino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremonini</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Corticotroph adenoma of the pituitary in a patient with X-linked adrenal hypoplasia congenita due to a novel mutation of the DAX-1 gene.</article-title>
                <source>Eur J Endocrinol</source>
                <volume>153</volume>
                <fpage>211</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16061826</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.domenice.2001.4068">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Domenice</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Latronico</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brito</surname>
                    <given-names>VN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnhold</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kok</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendonca</surname>
                    <given-names>BB</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Adrenocorticotropin-dependent precocious puberty of testicular origin in a boy with X-linked adrenal hypoplasia congenita due to a novel mutation in the DAX1 gene.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>86</volume>
                <fpage>4068</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">11549627</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.ferrazdesouza.2009.678">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferraz-de-Souza</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mallet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson-Davies</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cogram</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerrelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beuschlein</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morel</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huebner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>CBP/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 2, and pre-B-cell leukemia transcription factor 1 in human adrenal development and disease.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>94</volume>
                <fpage>678</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">18984668</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.franzese.2005.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franzese</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunetti-Pierri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spagnuolo</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spadaro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valerio</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Inappropriate tall stature and renal ectopy in a male patient with X-linked congenital adrenal hypoplasia due to a novel missense mutation in the DAX-1 gene.</article-title>
                <source>Am J Med Genet A</source>
                <volume>135</volume>
                <fpage>72</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15800903</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.frapsauce.2011.724">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frapsauce</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legendre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibony</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandelbaum</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donadille</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siffroi</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christin-Maitre</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Birth after TESE-ICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation.</article-title>
                <source>Hum Reprod</source>
                <volume>26</volume>
                <fpage>724</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21227944</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.guclu.2010.1512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guclu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erturk</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cangul</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Puberty, stress and sudden death.</article-title>
                <source>Lancet</source>
                <volume>376</volume>
                <fpage>1512</fpage>
                <pub-id pub-id-type="pmid">21036276</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.ho.2004.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>ER</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>NR0B1A: an alternatively spliced form of NR0B1.</article-title>
                <source>Mol Genet Metab</source>
                <volume>83</volume>
                <fpage>330</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15589120</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.hossain.2004.1428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hossain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>GF</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Generation of two distinct functional isoforms of dosage-sensitive sex reversal-adrenal hypoplasia congenita-critical region on the X chromosome gene 1 (DAX-1) by alternative splicing.</article-title>
                <source>Mol Endocrinol</source>
                <volume>18</volume>
                <fpage>1428</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">15044589</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.iyer.2004.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iyer</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>ER</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Molecular mechanisms of DAX1 action.</article-title>
                <source>Mol Genet Metab</source>
                <volume>83</volume>
                <fpage>60</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">15464421</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.lalli.2003.1445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lalli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sassone-Corsi</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation.</article-title>
                <source>Mol Endocrinol</source>
                <volume>17</volume>
                <fpage>1445</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">12775766</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.landau.2010.448">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanukoglu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sack</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weintrob</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eliakim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shomrat</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosinovsky</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to NR0B1 gene mutations.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <year>2010</year>
                <month>Apr</month>
                <volume>72</volume>
                <fpage>448</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">19508677</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.lin.2006.3048">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>WX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozisik</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>To</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years&#x02019; experience.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>91</volume>
                <fpage>3048</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">16684822</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.liotta.1995.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liotta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maggio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casimiro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giuffre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Grutta</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Congenital adrenal hypoplasia and hearing loss. A case report.</article-title>
                <source>Minerva Pediatr</source>
                <volume>47</volume>
                <fpage>471</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8684342</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.mantovani.2006.685">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mantovani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Menis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borretta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radetti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bondioni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients.</article-title>
                <source>Eur J Endocrinol</source>
                <volume>154</volume>
                <fpage>685</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16645015</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.mantovani.2002.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mantovani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozisik</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romoli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borretta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Hypogonadotropic hypogonadism as a presenting feature of late-onset X-linked adrenal hypoplasia congenita.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>87</volume>
                <fpage>44</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11788621</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.mccabe.2001">
              <mixed-citation publication-type="book">McCabe ERB. Adrenal hypoplasias and aplasias. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, Vogelstein B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Diseases</italic>. Vol 3. 8 ed. New York, NY: McGraw-Hill; 2001:4263-74.</mixed-citation>
            </ref>
            <ref id="ahc.REF.merke.1999.1248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merke</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tajima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baron</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutler</surname>
                    <given-names>GB</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX1 gene.</article-title>
                <source>N Engl J Med</source>
                <volume>340</volume>
                <fpage>1248</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">10210708</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.meimaridou.2012.740">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meimaridou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowalczyk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guasti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frommolt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000fc;rnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banerjee</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saka</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapple</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metherell</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency.</article-title>
                <source>Nat Genet</source>
                <volume>44</volume>
                <fpage>740</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">22634753</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.ozisik.2003.417">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ozisik</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mantovani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Persani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck-Peccoz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>88</volume>
                <fpage>417</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">12519885</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.peter.1998.2666">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Peter</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viemann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Partsch</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sippell</surname>
                    <given-names>WG</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Congenital adrenal hypoplasia: clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>83</volume>
                <fpage>2666</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">9709929</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.reutens.1999.504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reutens</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>WX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habiby</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donohoue</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hindmarsh</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>84</volume>
                <fpage>504</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">10022408</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.sablin.2008.18390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sablin</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krylova</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingraham</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletterick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>105</volume>
                <fpage>18390</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19015525</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.scheys.2011.3430">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scheys</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heaton</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammer</surname>
                    <given-names>GD</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Evidence of adrenal failure in aging Dax1-deficient mice.</article-title>
                <source>Endocrinology</source>
                <volume>152</volume>
                <fpage>3430</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21733829</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.seminara.1999.4501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seminara</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crowley</surname>
                    <given-names>WF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the phenotypic spectrum in males and females.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>84</volume>
                <fpage>4501</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10599709</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.shaikh.2008.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shaikh</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingston</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besley</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padmakumar</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ismayl</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hellerud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Skewed X inactivation is associated with phenotype in a female with adrenal hypoplasia congenita.</article-title>
                <source>J Med Genet</source>
                <volume>45</volume>
                <fpage>e1</fpage>
                <pub-id pub-id-type="pmid">18762570</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.sikl.1948.323">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sikl</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1948</year>
                <article-title>Addison&#x02019;s disease due to congential adrenal hypoplasia of the adrenals in an infant aged 33 days.</article-title>
                <source>J Pathol Bacteriol</source>
                <volume>60</volume>
                <fpage>323</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18099667</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.tabarin.2000.321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tabarin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Recan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bex</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertagna</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christin-Maitre</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism.</article-title>
                <source>J Clin Invest</source>
                <volume>105</volume>
                <fpage>321</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10675358</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.tsai.2005.991">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tung</surname>
                    <given-names>YC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel deletion mutations of the DAX1 (NR0B1) gene in two Taiwanese families with X-linked adrenal hypoplasia congenita.</article-title>
                <source>J Pediatr Endocrinol Metab</source>
                <volume>18</volume>
                <fpage>991</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16355812</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.verrijn_stuart.2007.755">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verrijn Stuart</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozisik</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vroede</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giltay</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinke</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>An amino-terminal DAX1 (NR0B1) missense mutation associated with isolated mineralocorticoid deficiency.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>92</volume>
                <fpage>755</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">17164309</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.wang.2001.7988">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>ZJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffs</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hales</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>98</volume>
                <fpage>7988</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">11427738</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.wiltshire.2001.1093">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wiltshire</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Couper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodda</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achermann</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Variable presentation of X-linked adrenal hypoplasia congenita.</article-title>
                <source>J Pediatr Endocrinol Metab</source>
                <volume>14</volume>
                <fpage>1093</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11592565</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.xu.2009.1719">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammer</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Dax-1 and steroid receptor RNA activator (SRA) function as transcriptional coactivators for steroidogenic factor 1 in steroidogenesis.</article-title>
                <source>Mol Cell Biol</source>
                <volume>29</volume>
                <fpage>1719</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">19188450</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.zachmann.1992.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zachmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchs</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prader</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Progressive high frequency hearing loss: an additional feature in the syndrome of congenital adrenal hypoplasia and gonadotropin deficiency.</article-title>
                <source>Eur J Pediatr</source>
                <volume>151</volume>
                <fpage>167</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">1601004</pub-id>
              </element-citation>
            </ref>
            <ref id="ahc.REF.zhang.1998.855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilain</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burris</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anyane-Yeboa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burghes</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitayat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chudley</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertner</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klingensmith</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamoto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>New</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagon</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pappas</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quigley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenthal</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baxter</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletterick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>ER</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>DAX1 mutations map to putative structural domains in a deduced three-dimensional model.</article-title>
                <source>Am J Hum Genet</source>
                <volume>62</volume>
                <fpage>855</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">9529340</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ahc.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ahc.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 October 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 May 2009 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>1 August 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>10 December 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 November 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>March 2001 (ev) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
